Jicheng Y. Lv

Key Laboratory Of Renal Disease
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 179 publications

Telitacicept for IgA Nephropathy. Reply.

Telitacicept for IgA Nephropathy. Reply.

Journal: The New England journal of medicine

Published: September 02, 2026

Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial.

Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial.

Journal: JAMA

Published: June 04, 2026

Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.

Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.

Journal: The New England journal of medicine

Published: May 13, 2026

Clinical Decision Support for Chronic Kidney Disease in Primary Care: A Cluster Randomized Clinical Trial.

Clinical Decision Support for Chronic Kidney Disease in Primary Care: A Cluster Randomized Clinical Trial.

Journal: JAMA network open

Published: May 08, 2026

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: April 07, 2026

Efficacy and safety of sibeprenlimab in IgA nephropathy: interim analysis of the China cohort in the phase 3 VISIONARY trial.

Efficacy and safety of sibeprenlimab in IgA nephropathy: interim analysis of the China cohort in the phase 3 VISIONARY trial.

Journal: Clinical kidney journal

Published: April 01, 2026

Glucocorticoid-Modulated Molecular Signatures and Prediction of Treatment Efficacy in IgA Nephropathy.

Glucocorticoid-Modulated Molecular Signatures and Prediction of Treatment Efficacy in IgA Nephropathy.

Journal: Journal of the American Society of Nephrology : JASN

Published: March 21, 2026

Beyond galactose deficiency: redefining pathogenic IgA in IgA nephropathy.

Beyond galactose deficiency: redefining pathogenic IgA in IgA nephropathy.

Journal: Kidney international

Published: February 28, 2026

Therapeutic efficacy and antigenicity of a novel PEGylated IgA protease in preclinical models of IgA nephropathy.

Therapeutic efficacy and antigenicity of a novel PEGylated IgA protease in preclinical models of IgA nephropathy.

Journal: Kidney international

Published: January 16, 2026

Ultrasensitive Immunoassay Using a Novel Galactose-Deficient IgA1 Antibody and Its Clinical Application in the Diagnosis of IgAN.

Ultrasensitive Immunoassay Using a Novel Galactose-Deficient IgA1 Antibody and Its Clinical Application in the Diagnosis of IgAN.

Journal: Kidney international reports

Published: January 04, 2026

Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) Trial.

Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) Trial.

Journal: American journal of nephrology

Published: December 09, 2025

Association between total bilirubin levels and the risk of acute kidney injury: a large hospital- based cohort study.

Association between total bilirubin levels and the risk of acute kidney injury: a large hospital- based cohort study.

Journal: BMC nephrology

Published: December 04, 2025

Showing 1-12 of 179

Last Updated: 09/26/2026